Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DVG1O0
|
|||
| Drug Name |
Daxdilimab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Alopecia areata [ICD-11: ED70.2] | Phase 2 | [1] | |
| Dermatomyositis [ICD-11: 4A41.0] | Phase 2 | [2] | ||
| Discoid lupus erythematosus [ICD-11: EB51.0; ICD-10: L93.2; ICD-9: 695.4] | Phase 2 | [3] | ||
| Lupus nephritis [ICD-11: 4A40.0Y] | Phase 2 | [4] | ||
| Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 2 | [5] | ||
| Company |
HORIZON
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte immunoglobulin-like receptor subfamily A member 4 (LILRA4) | Target Info | . | [6] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05368103) A Phase 2A, Open Label, Proof of Concept Trial of Daxdilimab for the Treatment of Moderate To Severe Alopecia Areata. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT05669014) A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Daxdilimab Subcutaneous Injection in Adult Participants With Inadequately Controlled Dermatomyositis or Anti-synthetase Inflammatory Myositis. U.S.National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT05591222) A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Investigate the Efficacy and Safety of Daxdilimab Subcutaneous Injection in Reducing Disease Activity in Adult Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus. U.S.National Institutes of Health. | |||
| REF 4 | ClinicalTrials.gov (NCT05540665) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy and Safety of Daxdilimab in Adult Participants With Active Proliferative Lupus Nephritis. U.S.National Institutes of Health. | |||
| REF 5 | ClinicalTrials.gov (NCT05430854) An Open-Label Extension Study To Evaluate The Long- Term Safety And Tolerability Of Daxdilimab (Hzn-7734) In Subjects With Systemic Lupus Erythematosus. U.S.National Institutes of Health. | |||
| REF 6 | Emerging drugs for the treatment of alopecia areata. Expert Opin Emerg Drugs. 2022 Dec;27(4):379-387. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.